This latest equity financing includes support from new US and international institutional investors, including a wholly-owned subsidiary of the Abu Dhabi Investment Authority, BB Biotech AG, Julius Baer, Singapore-based EDBI, and Sequoia Capital China.
Existing investors that also participated include Fidelity Management and Research company, Pictet, Viking Global Investors, ArrowMark Partners, and Alexandria Venture Investments.
The funding will help drive the company's continued execution of its rapidly growing pipeline of 19 development candidates including 10 programmes in clinical trials.
Proceeds will also be used to further Moderna's investment in its research engine and other 2018/2019 priorities.
Privately held Moderna is developing mRNA vaccines and therapeutics as a new class of medicines for infectious diseases, cancer (immuno-oncology), rare liver diseases, cardiovascular and pulmonary diseases, through proprietary development and collaborations with strategic partners.
AstraZeneca announces grant of PRIME eligibility by EMA for MEDI8897
AstraZeneca reports grant of Breakthrough Therapy Designation by US FDA for MEDI8897
Verseon Reports First Dosing in Phase 1 Trial on New Precision Oral Anticoagulant
Valbiotis Expands Board of Directors with the Appointment of Murielle Cazaubiel
AstraZeneca's Forxiga receives positive opinion from EU CHMP
Alexion, Caelum Biosciences Team to Develop Targeted Therapy for Light Chain Amyloidosis
Inotrem Extends Its License Agreement for the Biomarker Soluble TREM-1 to Cardiovascular Diseases